2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
485
Carcinoma, Non-Small-Cell Lung
440
Prostatic Neoplasms
292
Lung Neoplasms
170
Stomach Neoplasms
140
Neoplasms
114
Squamous Cell Carcinoma of Head and Neck
110
Neoplasm Metastasis
98
Head and Neck Neoplasms
97
Esophageal Neoplasms
71
Ovarian Neoplasms
57
Pancreatic Neoplasms
42
Urinary Bladder Neoplasms
39
Sarcoma
39
Nasopharyngeal Carcinoma
36
Carcinoma, Squamous Cell
30
Triple Negative Breast Neoplasms
28
Carcinoma, Ovarian Epithelial
28
Adenocarcinoma of Lung
27
Adenocarcinoma
27
Esophageal Squamous Cell Carcinoma
26
Parkinson Disease 4, Autosomal Dominant Lewy Body
23
Carcinoma, Transitional Cell
23
Adenocarcinoma Of Esophagus
23
Breast Neoplasms, Male
22
Recurrence
21
Unspecified Adult Solid Tumor, Protocol Specific
20
Inflammatory Breast Neoplasms
20
Fallopian Tube Neoplasms
20
Melanoma
18
Interventions
Mitomycin
3
vofatamab
2
pembrolizumab
2
Standard of Care
2
Cystectomy
2
B701 protein, Human herpesvirus 6
2
valrubicin
1
trifluridine tipiracil drug combination
1
testosterone 17 beta-cypionate
1
palbociclib
1
enfortumab vedotin
1
atezolizumab
1
Water
1
Valsartan
1
Urinary Diversion
1
Tranexamic Acid
1
Therapeutics
1
Testosterone Propionate
1
Sunitinib
1
Stents
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Practice Guidelines as Topic
1
Nephrotomy
1
Nephrostomy, Percutaneous
1
Methyltestosterone
1
Immune Checkpoint Inhibitors
1
Ice
1
Hydroxychloroquine
1
Health Information Exchange
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urologic Diseases
×
Docetaxel
×
Clear all
NCT02401542
2020-03-09
FIERCE-21
Rainier Therapeutics
Phase 1/2
Terminated
71 enrolled
9 charts